Ardelyx, Inc.(ARDX)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $3.33 – $8.40
- YTD
- -43.09%
- IV Rank (30D)
- 84.25
- Straddle Price
- $0.73
- P/C Vol Ratio
- 0.68
- Market Cap
- $0.9B
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.94% |
| Beta vs SPY | 0.94 |
| Cost of Equity (CAPM) | 9.66% (VRP-adj) |
| WACC | 8.65% |
| Volatility Risk Premium | +185.4pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +9.6% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -37.4% |
| Book / Price | 17.4% |
| Gross Margin (TTM) | 94.4% |
| FCF Margin (TTM) | -4.0% |
| Debt / Equity | 1.69 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $4.26 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $3.66 |
| Bollinger Width / SMA20 | 481.7% (drives anchor stability) |
| Net Debt | $0.2B |
| Market Cap | $1B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 29.2× · 5 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.3× · 6 peers |
| Peer P/B | $3.88 | 16% | median 6.4× · 7 peers |
| Peer P/S | $11.71 | 16% | median 5.8× · 8 peers |
| Market Anchor (SMA50) | $4.26 | 69% | stability 85% (BB-width) |
| Options Expected (B-L 30d) | $3.38 | 0% | 7 strikes · skew -0.02 |
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $0.9B
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on…
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +9.87% | 6 |
| Feb | -5.88% | 6 |
| Mar | +4.00% | 6 |
| Apr | -1.06% | 6 |
| May | -6.75% | 6 |
| Jun | -3.12% | 6 |
| Jul | -9.90% | 6 |
| Aug | +2.73% | 6 |
| Sep | -1.64% | 6 |
| Oct | -3.80% | 5 |
| Nov | -3.47% | 5 |
| Dec | +13.16% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 7/10)
Key Drivers:
- Technical indicators suggest a strong bearish momentum, with MACD and Stochastic signals aligning to confirm the downtrend.
- Recent news sentiment is mixed, but the negative headlines from Spherix Global Insights outweigh positive reports.
Primary Risks:
- The stock's beta of 0.8 indicates moderate volatility, which may amplify losses if the market corrects.
- Options activity suggests a bearish market expectation, with put-call volume and open interest ratios favoring puts.
Investment Thesis: ARX is likely to continue its downtrend due to mixed news sentiment and technical signals aligning against it. However, investors should consider hedging strategies or risk management approaches to mitigate potential losses.
Recent News Sentiment Impact: The negative headlines from Spherix Global Insights have dampened investor sentiment, contributing to the bearish momentum.
Technical Analysis
Trend Direction: Short-term (1-4 weeks) BEARISH, Medium-term (1-3 months) BEARISH
Support/Resistance Levels:
- Lower Bollinger Band: $3.66
- Middle Line: $3.87
- Upper Band: $4.09
Momentum Signals:
- RSI (14): 32.35 (neutral)
- MACD: -0.26 / Signal: 0.04 / Histogram: -0.30 (bearish)
Volume Analysis:
- Volume SMA 20: 4362503.87
- On-Balance Volume (OBV): -44516206.47
News & Sentiment Analysis
Recent Headlines Summary: The news headlines are mixed, with negative reports from Spherix Global Insights and a positive article about the appointment of Rajani Dinavahi, MD, as Chief Medical Officer.
Sentiment Assessment: NEUTRAL (Aggregate sentiment)
Catalyst Identification: Earnings data is not available, but investors should monitor upcoming regulatory changes and product launches for potential catalysts.
Market Narrative: The recent news sentiment aligns with the bearish technical signals, suggesting a continued downtrend.
Risk & Volatility Assessment
Risk Assessment: ARX has moderate volatility (beta 0.8), which may amplify losses if the market corrects.
Volatility Regime: CURRENT VERSUS HISTORICAL VOLATILITY LEVELS The current volatility level is relatively high compared to historical averages, indicating a potentially more volatile market environment.
Options Market Signals:
- IV Rank: 59.5% (Medium)
- Current IV: 179.2%
- Expected Move: $0.57 (42 DTE), 7-DTE: $0.38
Downside Protection: The stock's lower Bollinger Band ($3.66) and support levels from moving averages provide some downside protection.
Market Context & Positioning
Sector Performance: ARX is underperforming the overall market, with a relative strength of -25% compared to the sector average.
Institutional Activity: Volume patterns suggest institutional interest in buying pressure is low.
Correlation Analysis: The stock's correlation with the market is relatively weak (R-squared 0.17), indicating a potential divergence from the broader market trend.
Relative Valuation: ARX is trading within its historical range, but the bearish momentum suggests it may be due for a correction.
Key Levels & Action Items
Critical Price Levels:
- Lower Bollinger Band: $3.66
- Middle Line: $3.87
- Upper Band: $4.09
Breakout/Breakdown Levels:
- Resistance: $4.09 (upper band)
- Support: $3.66 (lower band)
Time-Sensitive Catalysts:
- Earnings data is not available, but monitor upcoming regulatory changes and product launches.
Risk Management: Consider stop-loss levels at the lower Bollinger Band ($3.66) or the middle line ($3.87), and adjust position sizing accordingly based on market conditions.
By analyzing the stock's technical indicators, news sentiment, and risk metrics, it is clear that ARX is likely to continue its downtrend due to mixed news sentiment and technical signals aligning against it. However, investors should consider hedging strategies or risk management approaches to mitigate potential losses.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-10-31 | After-Close | 13.91% | 3.34% | 0.24x | Within |
| 2025-02-20 | Pre-Market | 13.36% | 9.62% | 0.72x | Within |
| 2025-05-01 | After-Close | 19.14% | 25.18% | 1.32x | Exceeded |
| 2025-08-04 | After-Close | 20.05% | 16.86% | 0.84x | Within |
| 2025-10-30 | After-Close | 25.95% | 20.96% | 0.81x | Within |
| 2026-01-08 | Pre-Market | 15.96% | 20.88% | 1.31x | Exceeded |
| 2026-04-30 | After-Close | 18.56% | 8.69% | 0.47x | Within |
| 2026-08-06 | After-Close | 16.55% | 19.76% | 1.19x | Exceeded |
- IV Rank (30D)
- 84.25
- IV Rank (7D)
- 84.25
- Avg IV
- 217.9%
- Straddle (30D)
- $0.73
- Straddle (7D)
- $0.73
- P/C Volume
- 0.68
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
- Beta (1Y vs SPY)
- 0.81
- Correlation (SPY)
- 17.0%
- R²
- 0.03
- Ann. Volatility
- 61.7%
- SPY Volatility
- 13.0%
Moderate volatility - stock generally follows market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | ORACLE INVESTMENT MANAGEMENT INC | $3.50M | 28.49% | 2025-12-31 |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $1.56M | 12.69% | 2026-06-30 |
| 3 | MILLENNIUM MANAGEMENT LLC Custodian | $1.53M | 12.46% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $1.37M | 11.12% | 2026-06-30 |
| 5 | Stonepine Capital Management, LLC | $1.05M | 8.55% | 2026-06-30 |
| 6 | JANE STREET GROUP, LLC Custodian | $875.16K | 7.13% | 2026-06-30 |
| 7 | SIMPLEX TRADING, LLC Custodian | $773.67K | 6.30% | 2026-06-30 |
| 8 | Caption Management, LLC | $765.00K | 6.23% | 2026-06-30 |
| 9 | CITADEL ADVISORS LLC Custodian | $442.68K | 3.60% | 2026-06-30 |
| 10 | RAYMOND JAMES FINANCIAL INC Custodian | $250.00K | 2.04% | 2026-06-30 |
| 11 | WOLVERINE TRADING, LLC Custodian | $171.72K | 1.40% | 2025-09-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $2.03M | 28.61% | 2026-06-30 |
| 2 | CITADEL ADVISORS LLC Custodian | $1.55M | 21.74% | 2026-06-30 |
| 3 | JANE STREET GROUP, LLC Custodian | $1.05M | 14.76% | 2026-06-30 |
| 4 | Caption Management, LLC | $1.02M | 14.35% | 2026-06-30 |
| 5 | SIMPLEX TRADING, LLC Custodian | $388.62K | 5.47% | 2026-06-30 |
| 6 | MILLENNIUM MANAGEMENT LLC Custodian | $365.67K | 5.14% | 2026-06-30 |
| 7 | WOLVERINE TRADING, LLC Custodian | $297.83K | 4.19% | 2025-09-30 |
| 8 | IMC-Chicago, LLC Custodian | $204.51K | 2.88% | 2026-06-30 |
| 9 | GROUP ONE TRADING LLC Custodian | $202.98K | 2.86% | 2026-06-30 |
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-25 | Susan Hohenleitner | Chief Financial Officer | Sell (S) | −1,558 | $3.86 | -$6.0K | EDGAR |
| 2026-08-25 | Joseph James Reilly | See Remarks | Sell (S) | −3,982 | $3.86 | -$15.4K | EDGAR |
| 2026-08-25 | James Parker Brady | Chief Human Resources Officer | Sell (S) | −15,136 | $3.86 | -$58.4K | EDGAR |
| 2026-08-25 | John E Bishop | See Remarks | Sell (S) | −19,750 | $3.86 | -$76.2K | EDGAR |
| 2026-08-25 | Mike Kelliher | Chief Business Officer | Sell (S) | −7,758 | $3.86 | -$29.9K | EDGAR |
| 2026-08-25 | MICHAEL RAAB | President & CEO | Sell (S) | −58,574 | $3.86 | -$225.9K | EDGAR |
| 2026-08-25 | Laura A Williams | Chief Patient Officer | Sell (S) | −10,739 | $3.86 | -$41.4K | EDGAR |
| 2026-08-25 | Eric Duane Foster | Chief Commercial Officer | Sell (S) | −8,562 | $3.86 | -$33.0K | EDGAR |
| 2026-07-17 | MICHAEL RAAB | President & CEO | Mixed | −20,834 | $3.70 | -$190.3K | EDGAR |
| 2026-06-22 | Laura A Williams | Chief Patient Officer | Mixed | −50,898 | $4.62 | -$459.8K | EDGAR |
| 2026-06-18 | DAVID M MOTT | Director | Award (A) | +46,737 | — | EDGAR | |
| 2026-06-18 | William C Bertrand JR | Director | Award (A) | +38,800 | — | EDGAR | |
| 2026-06-18 | Muna Bhanji | Director | Award (A) | +26,455 | — | EDGAR | |
| 2026-06-18 | Onaiza Cadoret-Manier | Director | Award (A) | +26,455 | — | EDGAR | |
| 2026-06-18 | Richard J Rodgers | Director | Award (A) | +26,455 | — | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | PETER J BARRIS | 10%+ Owner | 9,579,210 | $33.53M | $84.96M | 7 | 2019-12-09 |
| 2 | M JAMES BARRETT | 10%+ Owner | 9,169,210 | $32.09M | $31.61M | 5 | 2018-05-30 |
| 3 | KRISHNA KITTU KOLLURI | 10%+ Owner | 8,752,543 | $30.63M | $84.99M | 4 | 2016-07-20 |
| 4 | NEA Partners 12, Limited Partnership | 10%+ Owner | 8,541,623 | $29.90M | $0 | 2 | 2020-06-12 |
| 5 | PATRICK J KERINS | 10%+ Owner | 8,097,725 | $28.34M | $31.67M | 7 | 2020-06-12 |
| 6 | New Enterprise Associates 12, Limited Partnership | 10%+ Owner | 8,086,401 | $28.30M | $95.00M | 5 | 2020-06-12 |
| 7 | RYAN D DRANT | 10%+ Owner | 7,489,426 | $26.21M | $20.00M | 2 | 2015-06-09 |
| 8 | DAVID M MOTT | Director | 6,831,841 | $23.91M | $65.06M | 31 | 2026-06-18 |
| 9 | FOREST BASKETT | 10%+ Owner | 6,207,480 | $21.73M | $80.59M | 10 | 2021-12-27 |
| 10 | Mohamad Makhzoumi | 10%+ Owner | 3,482,186 | $12.19M | $0 | 1 | 2019-12-09 |
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-21 | Hohenleitner Susan | Officer | 2,650 | $10.7K | 2026-08-21 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-21 | Brady James Parker | Officer | 19,700 | $79.4K | 2026-08-21 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-21 | Reilly Joseph James | Officer | 4,700 | $18.9K | 2026-08-21 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-21 | Foster Eric Duane | Officer | 11,900 | $48.0K | 2026-08-21 | Morgan Stanley Smith Barney LLC,… | — | EDGAR |
| 2026-08-21 | Kelliher Mike | Officer | 10,500 | $42.3K | 2026-08-21 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-21 | Williams Laura A | Officer | 10,500 | $42.3K | 2026-08-21 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-21 | RAAB MICHAEL | Officer | 44,500 | $179.3K | 2026-08-21 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-21 | Bishop John E | Officer | 25,500 | $102.8K | 2026-08-21 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-18 | LAURA WILLIAMS | Officer | 81,898 | $478.3K | 2026-06-18 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-17 144/A | RAAB MICHAEL | Officer, Director | 41,666 | $236.7K | 2026-06-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 5.9 |
| P/S Ratio | 2.0 |
| EV/EBITDA | -32.3 |
| TTM Revenue | $0.5B |
| TTM Net Income | $-0.1B |
| TTM EPS | $-0.23 |
| ROE | -37.4% |
| Debt/Equity | 1.69 |